Company intelligence / Profile preview
Yantai Dongcheng Biochemicals
- Ownership
- Private
- Employees
- ~2469
- Development stage
- Other
Overview
Yantai Dongcheng Biochemicals has a robust portfolio of biochemical APIs (including heparin sodium and chondroitin sulfate, which have obtained global regulatory certifications and approvals), radiopharmaceuticals (including approved diagnostic and therapeutic agents for cancer and thyroid disease), and diagnostic kits (e.g. for H. pylori); more than 29 clinical trials have been registered and many products are commercialized[2][5][8][10].
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesHematologyOncology
- Modalities
- BiologicSmall moleculeRadiopharmaceuticalDiagnostic radiopharmaceuticalProtein
- Industry
- Pharma
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Yantai Dongcheng Biochemicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yantai Dongcheng Biochemicals.